India's fourth largest pharmaceutical company in terms of sales, the Dilip Sanghvi-led Sun Pharmaceutical Industries, has informed that U.S. Food and Drug Administration (FDA) has finally approved its first generic version of the divalproex sodium tablets.

These generic versions of divalproex sodium delayed release 125 mg, 250 mg and 500 mg (valproic acid activity) tablets are bio-equivalent to Depakote delayed release tablets distributed by Abbott Laboratories.

The drug used to treat epileptic seizures, manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches.

Depakote delayed release tablets have annual sales of about $750 million in the U.S. The company will shortly launch the product in the market.